Poster Presentation Australian Diabetes Society and the Australian Diabetes Educators Association Annual Scientific Meeting 2017

Evidence of a strong association between frequency of flash glucose monitoring and glucose control measures during real world usage (#308)

Gary Hayter 1 , Yongjin Xu 1 , Timothy Dunn 1 , Michael Nobes 2
  1. Abbott, Alameda, CALIFORNIA, United States
  2. Abbott Diabetes Care, Doncaster

Background and Aims:

The aim was to evaluate association of the real-world scanning with flash glucose monitoring (FreeStyle Libre®) and glucose control measures.  FreeStyle Libre is a sensor-based glucose monitor, and the reader scans the sensor to collect the current glucose and glucose trend, along with up to 8 hours of glucose readings automatically stored every 15 minutes.   When connected to the PC-based software with an active internet connection, the reader’s 90-day memory is de-identified and uploaded to a database.

Methods:

For analysis, sensors were required to have at least 120 hours of operation, and all sensors were grouped per reader, resulting in 50,831 readers with 279,446 sensors (86.4 million monitoring hours by 63.8 million scans).  Twenty equally-sized groups by scan rate were analyzed (n=2,542 each). 

Results:

Users performed an average of 16.3 scans per day (median:14, interquartile range: 10-20).  Estimated HbA1c reduced (p<0.001) as scan rate increased, from 8.0% to 6.7% from the lowest (mean 4.4 scans/day) to highest (mean 48.1 scans/day) groups, while simultaneously time below 70, 55 and 45 mg/dL (3.9, 3.1 and 2.5 mmol/L) decreased by 15%, 40% and 49%, respectively (all p<0.001).  Time above 180 mg/dL (10.0 mmol/L) decreased from 10.4 to 5.7 h/day (44%, p<0.001), and time in range 70-180 mg/dL (3.9-10.0 mmol/L) increased from 12.0 to 16.8 h/day (40%, p<0.001).

Conclusions:

In real-world use, higher rates of scanning to self-monitor glucose were found to strongly associate with improved glucose measures, including decreased mean glucose and time in hyper- and hypoglycaemia as well as increased time in range.

Disclosure Statement:

All work was funded by and the authors are employees of Abbott Diabetes Care.  These data were presented at the 10th International Conference on Advanced Technologies & Treatments for Diabetes, Paris, France, 15-18 February, 2017